Wells Fargo & Company Raises Integer (NYSE:ITGR) Price Target to $84.00

Integer (NYSE:ITGR) had its price objective raised by Wells Fargo & Company from $72.00 to $84.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s target price would suggest a potential downside of 0.94% from the company’s previous close.

A number of other research analysts have also issued reports on ITGR. Raymond James Financial reiterated an “outperform” rating and set a $95.00 target price (down previously from $143.00) on shares of Integer in a research report on Friday, October 24th. Piper Sandler reduced their price objective on shares of Integer from $155.00 to $82.00 and set an “overweight” rating for the company in a research report on Friday, October 24th. Wall Street Zen lowered shares of Integer from a “buy” rating to a “hold” rating in a research report on Sunday, January 25th. Argus cut Integer from a “buy” rating to a “hold” rating in a report on Friday, October 24th. Finally, Truist Financial lifted their price target on Integer from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $101.25.

Integer Trading Up 2.2%

ITGR stock opened at $84.80 on Friday. Integer has a 52-week low of $62.00 and a 52-week high of $136.06. The company has a quick ratio of 2.45, a current ratio of 3.32 and a debt-to-equity ratio of 0.69. The firm has a market cap of $2.97 billion, a P/E ratio of 29.55, a PEG ratio of 0.77 and a beta of 0.77. The company’s 50-day simple moving average is $82.83 and its 200-day simple moving average is $88.12.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, February 19th. The medical equipment provider reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.06. The firm had revenue of $472.06 million during the quarter, compared to analyst estimates of $462.73 million. Integer had a return on equity of 13.26% and a net margin of 5.55%.Integer’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.43 EPS. Integer has set its FY 2026 guidance at 6.290-6.780 EPS. As a group, equities analysts forecast that Integer will post 6.01 EPS for the current fiscal year.

Integer announced that its Board of Directors has initiated a share buyback plan on Tuesday, November 4th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the medical equipment provider to buy up to 8.3% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Institutional Trading of Integer

Institutional investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. raised its stake in shares of Integer by 800,382.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 280,169 shares of the medical equipment provider’s stock valued at $21,974,000 after acquiring an additional 280,134 shares during the period. Corient Private Wealth LLC acquired a new stake in Integer in the 4th quarter valued at approximately $535,000. Mercer Global Advisors Inc. ADV raised its position in Integer by 1.4% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 41,049 shares of the medical equipment provider’s stock valued at $3,219,000 after purchasing an additional 555 shares during the period. XTX Topco Ltd purchased a new stake in Integer in the fourth quarter valued at approximately $4,581,000. Finally, Voloridge Investment Management LLC acquired a new position in Integer during the fourth quarter worth $14,694,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Trending Headlines about Integer

Here are the key news stories impacting Integer this week:

• Positive Sentiment: Q4 results beat expectations — EPS $1.76 vs. $1.70 est and revenue $472.1M vs. $462.7M; full-year results showed 8% sales growth and strong adjusted EPS growth, supporting the company narrative of improving margins and growth execution. Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2025
• Positive Sentiment: Truist raised its price target to $97 and kept a “buy” rating, signaling an analyst view of meaningful upside versus the current level. Benzinga — Truist raises target
• Neutral Sentiment: Wells Fargo also raised its target (to $84) but kept an “equal weight” rating — a modest signal that the stock is fairly valued near current levels rather than a clear endorsement. Benzinga — Wells Fargo raises target
• Neutral Sentiment: Full earnings materials (slide deck and call transcript) are available for deeper review of segment trends, backlog and margin drivers — useful for investors deciding if the beat is sustainable. Q4 Results – Earnings Call Presentation Q4 Earnings Call Transcript
• Negative Sentiment: Market reaction was mixed: some investors sold after management’s FY2026 guidance was viewed as softer than hoped, leading to an earlier pullback. Zacks notes shares fell despite the beat because guidance tempered enthusiasm. ITGR Shares Down Despite Q4 Earnings & Revenues Beat Estimates
• Negative Sentiment: Wider context: guidance midpoint and revenue outlook left some analysts noting modest downside risk versus certain targets, which could cap upside until visibility improves. MarketBeat — Earnings & Guidance Details

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.